Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: Indinavir sulfate, Stavudine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Whitehouse Station, New Jersey

Conditions: HIV Infections
Interventions: Indinavir sulfate, Abacavir sulfate, Amprenavir, Lamivudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 15 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: New York, New York • Providence, Rhode Island

Conditions: HIV Infections
Interventions: Indinavir sulfate; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Whitehouse Station, New Jersey

Conditions: HIV Infections
Interventions: NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT), NNRTIs (EFV, NVP), PIs (AMP, IDV, LPV/r, NFV, SQV, RTV); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 30 Days to 18 Years
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 29
States / cities: Alhambra, California • Long Beach, California • Los Angeles, California + 22 more

Conditions: AIDS Dementia Complex, HIV Infections
Interventions: CPI-1189; Drug
Lead sponsor: Centaur Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: HIV Infections, Cardiovascular Diseases, Hypertension
Interventions: Indinavir sulfate, Ritonavir, Amlodipine, Diltiazem HCl; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2004
U.S. locations: 9
States / cities: San Francisco, California • Stanford, California • Denver, Colorado + 6 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV-DDI
Interventions: Riociguat (Adempas, BAY 63-2521), ATRIPLA, COMPLERA, STRIBILD, TRIUMEQ, Antiretroviral protease inhibitor; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Orlando, Florida • Boston, Massachusetts

Conditions: HIV Infections
Interventions: Indinavir sulfate, Ritonavir; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Los Angeles, California • Miami, Florida • Chicago, Illinois + 5 more

Conditions: HIV Infections
Interventions: EVG, RTV, ARV regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: Not listed
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 47
States / cities: Pheonix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 44 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine, Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 14 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Sargramostim; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 39
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 22 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Ritonavir, Nevirapine, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 17 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 58
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 39 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine/Zidovudine, Nelfinavir mesylate, Efavirenz; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 49
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 32 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine, Zidovudine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Redwood City, California + 9 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Efavirenz; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: San Diego, California • San Francisco, California • Denver, Colorado + 5 more

Conditions: HIV Infections, Hemophilia A
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older · Male only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 7
States / cities: San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 1,750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1997
U.S. locations: 85
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 43 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Rifabutin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 8
States / cities: Los Angeles, California • Denver, Colorado • Miami, Florida + 3 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Delavirdine mesylate, Lamivudine, Zidovudine; Drug
Lead sponsor: Pharmacia and Upjohn; Industry
Eligibility: 14 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Peapack, New Jersey

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 16 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: Birmingham, Alabama • Fort Lauderdale, Florida • Tampa, Florida + 6 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Ritonavir, Lamivudine, Stavudine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: Miami, Florida • Albany, New York • Stony Brook, New York

Conditions: HIV Infections
Interventions: Indinavir sulfate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 1,900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1997
U.S. locations: 14
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 10 more

Search by objective public record fields.

A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients

A Study of a Combination of Four Drugs in Patients With Recent HIV Infection

A Study of L-735,524 in HIV-Positive Children and Adolescents

Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children

Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination Anti-HIV Drug Therapy

Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers

The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients

Interaction With HIV Antiretroviral Agents

Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors

Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection

A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone

The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV Therapy

A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC

Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs

Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen

The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection

The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz

Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months

Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults

A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients

A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

The Addition of Indinavir to Anti-HIV Treatment in HIV-Infected Patients